FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates (Gore) announced today that the first patient has been enrolled in a U.S. Food and Drug Administration (FDA) approved IDE study for the 45 mm* GORE TAG® Thoracic Endoprosthesis for treatment of aneurysms of the descending thoracic aorta. Grayson Wheatley, MD, Arizona Heart Institute, enrolled the first patient in the multi-center clinical study, which will assess the safety and efficacy of the 45 mm GORE TAG Device for the primary treatment in patients with aortic inner diameters adjacent to the aneurysm ranging from 37 to 42 mm.
